Interface Biologics Overview

  • Year Founded
  • 2001

Year Founded

  • Status
  • Acquired/​Merged

  • Employees
  • 7

Employees

  • Latest Deal Type
  • M&A

Interface Biologics General Information

Description

Developer of biomedical polymer technology designed to improve the efficacy of medical devices and targeted delivery of drugs. The company's technology uses surface modification additives that are used in FDA-cleared medical devices and are clinically proven to reduce infection and thrombus-related complications and are applicable across a range of drug classes and medical specialties with a focus on ophthalmology, enabling clinicians to improve the safety and effectiveness of medical devices.

Contact Information

Ownership Status
Acquired/Merged
Financing Status
Formerly VC-backed
Corporate Office
  • MaRS Centre, South Tower, 101 College Street
  • Suite 300
  • Toronto, Ontario M5G 1L7
  • Canada
+1 (416)
Primary Industry
Drug Delivery
Other Industries
Other Devices and Supplies
Biotechnology
Vertical(s)
Corporate Office
  • MaRS Centre, South Tower, 101 College Street
  • Suite 300
  • Toronto, Ontario M5G 1L7
  • Canada
+1 (416)

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Interface Biologics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
9. Merger/Acquisition 03-Sep-2019 Completed Generating Revenue
8. Later Stage VC Completed Generating Revenue
7. Later Stage VC (Series B) 13-Jan-2015 Completed Generating Revenue
6. Later Stage VC 06-Dec-2011 Completed Generating Revenue
5. Later Stage VC (Series B) 10-Jan-2011 Completed Generating Revenue
4. Later Stage VC 11-Dec-2008 Completed Generating Revenue
3. Early Stage VC (Series A) 30-Sep-2004 Completed Generating Revenue
2. Seed Round 28-Jan-2002 $1M $1M Completed Generating Revenue
1. University Spin-Out 01-Jan-2001 Completed Startup
To view Interface Biologics’s complete valuation and funding history, request access »

Interface Biologics Patents

Interface Biologics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
EP-3796948-A1 Compositions and methods for delivering drugs to a vessel wall Inactive 22-May-2018
EP-3796948-A4 Compositions and methods for delivering drugs to a vessel wall Inactive 22-May-2018
US-11318232-B2 Compositions and methods for delivering drugs to a vessel wall Inactive 22-May-2018
US-20200188560-A1 Compositions and methods for delivering drugs to a vessel wall Active 22-May-2018
US-20220362440-A1 Compositions and methods for delivering drugs to a vessel wall Inactive 22-May-2018 A61L29/085
To view Interface Biologics’s complete patent history, request access »

Interface Biologics Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Interface Biologics Former Investors (8)

Investor Name Investor Type Holding Investor Since Participating Rounds
BDC Capital Growth/Expansion Minority
Covington Capital Corporation Venture Capital Minority
Genesys Capital Venture Capital Minority
MaRS Investment Accelerator Fund Venture Capital Minority
Ontario Centre of Innovation Not-For-Profit Venture Capital Minority
You’re viewing 5 of 8 investors. Get the full list »

Interface Biologics FAQs

  • When was Interface Biologics founded?

    Interface Biologics was founded in 2001.

  • Where is Interface Biologics headquartered?

    Interface Biologics is headquartered in Toronto, Canada.

  • What is the size of Interface Biologics?

    Interface Biologics has 7 total employees.

  • What industry is Interface Biologics in?

    Interface Biologics’s primary industry is Drug Delivery.

  • Is Interface Biologics a private or public company?

    Interface Biologics is a Private company.

  • What is Interface Biologics’s current revenue?

    The current revenue for Interface Biologics is .

  • How much funding has Interface Biologics raised over time?

    Interface Biologics has raised $31.5M.

  • Who are Interface Biologics’s investors?

    BDC Capital, Covington Capital Corporation, Genesys Capital, MaRS Investment Accelerator Fund, and Ontario Centre of Innovation are 5 of 8 investors who have invested in Interface Biologics.

  • When was Interface Biologics acquired?

    Interface Biologics was acquired on 03-Sep-2019.

  • Who acquired Interface Biologics?

    Interface Biologics was acquired by Evonik Industries.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process